Clinical Characteristics and Molecular Mechanism of Patients With Obstructive Sleep Apnea
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Zhiling Zhao
- Phone Number: +86 186 1280 8859
- Email: cysleep@163.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100020
- Recruiting
- Beijing Chaoyang Hospital Affiliated to Capital Medical University
-
Contact:
- Zhiling Zhao
- Phone Number: +86 186 1280 8859
- Email: cysleep@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with suspected obstructive sleep apnea (OSA) admitted to the sleep center of the respiratory Department of Beijing Chaoyang Hospital, Capital Medical University.
- Volunteer to participate in the study and sign an informed consent, and can complete at least 1 year of follow-up.
Exclusion Criteria:
- Patients with obstructive sleep apnea who have been treated with impermanent positive pressure ventilation;
- Pregnant or lactating women;
- Patients with severe respiratory failure requiring mechanical ventilation;
- Patients with severe heart, lung, liver, kidney, and central nervous system damage;
- Refuse to participate in follow-up visits and/or take biological samples.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Healthy controls
|
|
Severe OSA
|
|
Non-severe OSA
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Multiple-omics features
Time Frame: Within 24 hours of admission,and samples of patients receiving treatment were also collected six months and one year after treatment
|
ELISA ,proteomics and metabolomics were performed on blood, saliva, urine
|
Within 24 hours of admission,and samples of patients receiving treatment were also collected six months and one year after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-ke-450
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.